
Shubham Pant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2050960/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 2016, 24, 1150-1158.	8.2	114
2	Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2020, 155, 832.	4.3	105
3	A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. European Journal of Cancer, 2016, 56, 1-9.	2.8	76
4	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clinical Cancer Research, 2018, 24, 3253-3262.	7.0	71
5	Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Annals of Surgery, 2021, 273, 806-813.	4.2	61
6	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist, 2021, 26, 588-596.	3.7	42
7	Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study Journal of Clinical Oncology, 2021, 39, 299-299.	1.6	40
8	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Medicine, 2021, 10, 5041-5050.	2.8	35
9	Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Annals of Surgery, 2020, 271, 996-1002.	4.2	34
10	Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> ^{G12C} -Mutant Colorectal Cancer. JCO Precision Oncology, 2021, 5, 613-621.	3.0	31
11	Pancreas Cancer-Associated Pain Management. Oncologist, 2021, 26, e971-e982.	3.7	29
12	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. , 2022, 10, e003697.		28
13	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabineâ€based therapy with or without bevacizumab. Cancer, 2014, 120, 1780-1786.	4.1	23
14	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discovery, 2022, 12, 2330-2349.	9.4	22
15	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Scientific Reports, 2020, 10, 22087.	3.3	21
16	Clinical update on K-Ras targeted therapy in gastrointestinal cancers. Critical Reviews in Oncology/Hematology, 2018, 130, 78-91.	4.4	19
17	A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Investigational New Drugs, 2021, 39, 1089-1098.	2.6	19
18	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 614-618.	1.3	14

Shubham Pant

#	Article	IF	CITATIONS
19	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of Medical Internet Research, 2019, 21, e10348.	4.3	13
20	The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 3939-3947.	1.5	12
21	Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e153-e165.	3.8	12
22	Modified gemcitabine plus nabâ€paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Medicine, 2020, 9, 5406-5415.	2.8	9
23	Immunotherapy in Gastrointestinal Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 93-106.	1.6	7
24	PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer, 2022, 22, 14.	2.6	5
25	Immunotherapy in Gastrointestinal Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 259-272.	1.6	3
26	Combination Drug Development in BRAF Mutant Colorectal Cancer. Oncoscience, 2018, 5, 51-53.	2.2	1
27	Barriers to Pancreatic Cancer Clinical Trials Enrollment. Oncology, 2020, 34, .	0.5	1
28	Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Journal of Gastrointestinal Oncology, 2021, 12, 2268-2274.	1.4	0
29	Regarding HER2â€Amplified Biliary Tract Cancer. Oncologist, 2021, 26, e1664.	3.7	0
30	Incidence of Late Failure Following Myeloablative Conditioning with BuCy2 and Matched Sibling Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Blood, 2008, 112, 2172-2172.	1.4	0